Abstract
It is well recognized that medication adherence of rheumatoid arthritis (RA) patients is often poor. As less attention has been paid to physicians' adherence to targeted treatment, we aimed to investigate how it affects outcomes in aggressively treated early RA patients. In the new Finnish RA Combination Therapy (NEO-RACo) trial, 99 patients with early active RA were treated, targeting remission, with a combination of methotrexate, sulfasalazine, hydroxychloroquine, and low-dose prednisolone for 2 years, and randomized to receive infliximab or placebo for the initial 6 months. After 2 years, therapy was unrestricted while remission was still targeted. Patients were divided into tertiles by physicians' adherence to treat-to-target, which was evaluated with a scoring system during the initial 2 years. After 5 years of follow-up, the between-tertile differences in remission rates, 28-joint Disease Activity Score (DAS28) levels, radiological changes, cumulative days off work, and the use of anti-rheumatic medication were assessed. Follow-up data were available for 93 patients. Physicians' good adherence was associated with improved remission rates at 2-4 years and lower DAS28 levels throughout the follow-up. In a multivariable mode...Continue Reading
References
Mar 1, 1988·Arthritis and Rheumatism·F C ArnettH S Luthra
Oct 1, 1981·Arthritis and Rheumatism·R S PinalsR A Larsen
Jan 1, 1995·Arthritis and Rheumatism·M L PrevooP L van Riel
Feb 26, 1999·Patient Education and Counseling·H BrusO Wiegman
May 20, 1999·Lancet·T MöttönenC Friman
Oct 5, 2001·Medical Care·R Grol
Jul 21, 2004·Lancet·Catriona GrigorDuncan Porter
Dec 22, 2004·International Journal of Technology Assessment in Health Care·Christel BahtsevaniAnia Willman
Dec 31, 2005·Arthritis and Rheumatism·Ferdinand C BreedveldGeorge T Spencer-Green
Mar 29, 2007·Archives of Internal Medicine·Sunil KripalaniR Brian Haynes
Sep 20, 2007·Annals of the Rheumatic Diseases·M L HetlandUNKNOWN CIMESTRA study group
Feb 28, 2008·The Annals of Pharmacotherapy·Robert J DidomenicoGlen T Schumock
Apr 19, 2008·Annals of the Rheumatic Diseases·I HafströmUNKNOWN BARFOT Study Group
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee
Oct 28, 2010·The Annals of Pharmacotherapy·Gita Wasan PatelWilliam Bartek
Apr 2, 2011·Rheumatology·Patrick Verschueren, René Westhovens
Jun 28, 2011·International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care·Se-Won OhJee-In Hwang
Feb 4, 2012·Annals of the Rheumatic Diseases·Merete Lund HetlandUNKNOWN CIMESTRA study group
Jul 4, 2012·Annals of the Rheumatic Diseases·Marjatta Leirisalo-RepoUNKNOWN NEO-RACo Study Group
Nov 28, 2012·Arthritis Research & Therapy·Marloes VermeerMart A F J van de Laar
Aug 3, 2013·Annals of the Rheumatic Diseases·Vappu RantalaihoUNKNOWN NEO-RACo Study Group
Oct 29, 2013·Annals of the Rheumatic Diseases·Josef S SmolenDésirée van der Heijde
Dec 4, 2013·Annals of the Rheumatic Diseases·Vappu RantalaihoUNKNOWN FIN-RACo Study Group
Dec 18, 2013·American Heart Journal·Niteesh K ChoudhryWilliam H Shrank
Citations
Dec 25, 2015·Best Practice & Research. Clinical Rheumatology·Sehrash MahmoodRobert Landewé
Sep 22, 2016·Journal of Evaluation in Clinical Practice·Nasir Wabe, Michael D Wiese
Sep 30, 2016·Clinical Rheumatology·G AkdemirC F Allaart
Dec 6, 2017·Health Technology Assessment : HTA·Allan WailooAdam Young
Feb 9, 2018·Nature Reviews. Disease Primers·Josef S SmolenKazuhiko Yamamoto
Jul 13, 2019·Zeitschrift für Rheumatologie·C Fiehn, K Krüger
Sep 11, 2019·Journal of Clinical Medicine·Bogdan BatkoZbigniew Żuber
Sep 17, 2019·The Journal of Rheumatology·Alexandre SeprianoWalter P Maksymowych
Mar 31, 2016·Current Opinion in Rheumatology·Josef S Smolen
Aug 26, 2017·PloS One·Tuija VäänänenUNKNOWN NEO-RACo Study Group
Jan 15, 2019·Advances in Therapy·László GulácsiMárta Péntek
Dec 12, 2018·Journal of Cellular Physiology·Mojtaba AbbasiSaeed Aslani
Apr 30, 2020·Current Rheumatology Reviews·Priya Nijhawan, Tapan Behl